Table 1.

Patient characteristics

Characteristic	n (%)
Age, y
≤40	14 (40)
>40 to ≤50	6 (17)
>50 to ≤60	11 (31)
>60	4 (11)
Race/ethnicity
White, non-Hispanic/Latina	15 (43)
Hispanic/Latina	16 (46)
Other	4 (11)
Karnofsky performance status score
100	22 (63)
90	5 (14)
80	6 (17)
70	2 (6)
Body mass index, kg/m2
≥20 to <25	8 (23)
≥25 to <30	11 (31)
≥30 to <35	10 (29)
≥35	6 (17)
Smoking status
Current	9 (26)
Former	8 (23)
Never	18 (51)
FIGO stage (2009)
IB	12 (34)
IIA	2 (6)
IIB	8 (23)
IIIA	1 (3)
IIIB	11 (31)
IVA	1 (3)
Tumor histology
Squamous cell carcinoma	24 (69)
Adenocarcinoma	10 (29)
Adenosquamous carcinoma	1 (3)
Tumor grade
Moderately differentiated	12 (34)
Poorly differentiated	17 (49)
Unknown	6 (17)
Pretreatment imaging
PET/CT	33 (94)
MRI	16 (46)
Surgery
None (intact cervix)	32 (91)
Posthysterectomy, residual disease	1 (3)
Posthysterectomy, recurrent disease	2 (6)
No. of cisplatin cycles
≤3	3 (9)
4	9 (26)
5	22 (63)
6	1 (3)
No. of gemcitabine cycles
≤3	4 (11)
4	8 (23)
5	22 (63)
6	1 (3)
Radiation approach
Teletherapy
Extended (paraortic) field	3 (9)
Inguinal field	3 (9)
Simultaneous integrated boost	21 (60)
Parametrial boost	8 (23)
Stereotactic boost	3 (9)
Brachytherapy
Intracavitary tandem + ovoids/ring	32 (91)
Intracavitary cylinder	2 (6)
Interstitial implant	4 (11)
Treatment duration, d
≤60	30 (86)
>60 to ≤70	3 (9)*
>70	2 (6)*

Abbreviations: FIGO = International Federation of Gynecology and Obstetrics; MRI = magnetic resonance imaging; PET/CT = positron emission tomography/computed tomography.

^*Of 5 treatment durations >60 d, 4 were due to hospitalization and 1 (63 d) was due to a delay in boost scheduling.